print

Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol

author

Schwartz, Gregory G.

Szarek, Michael

Bittner, Vera A.

Diaz, Rafael

Goodman, Shaun G.

Viigimaa, Margus

corporate author

ODYSSEY Outcomes Committees and Investigators

statement of authorship

Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, and on behalf of ODYSSEY Outcomes Committees and Investigators, [Margus Viigimaa et al.]

source

Journal of the American College of Cardiology

publisher

American College of Cardiology

journal volume number month

Vol. 78, 5

year of publication

2021

pages

p. 421–433 : ill

url

https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102

https://doi.org/10.1016/j.jacc.2021.04.102

subject term

kolesterool

patsiendid

inhibiitorid

lipoproteiinid

lipoproteiinide ainevahetus

südame-veresoonkonna haigused

keyword

acute coronary syndrome

lipoprotein(a)

low-density lipoprotein cholesterol

PCSK9 inhibitor

ISSN

0735-1097

TalTech department

tervisetehnoloogiate instituut

language

inglise

Reserch Group

Research group on diagnostics and treatment technologies of hypertension and atherosclerosis